{
    "abstract": [],
    "body_text": [
        {
            "text": "Transmissible spongiform encephalopathies (TSEs) are neurodegenerative diseases which are characterized by the accumulation and deposition of a pathogenic isoform (PrP Sc ) of the host encoded cellular prion protein (PrP C ) designated PrP Sc . ",
            "section": "INTRODUCTION"
        },
        {
            "text": "Both isoforms share the same amino acid sequence but differ in conformation, resistance to proteinase K (PK), and pathogenicity. PrP Sc tends to oligomerize by a seeded polymerization mechanism followed by the formation of multimers and eventually of fibril structures. ",
            "section": "INTRODUCTION",
            "ref_spans": [
                {
                    "start": 107,
                    "end": 136,
                    "type": "bibr",
                    "text": "(Groschup et al., 1994, 1997)"
                }
            ]
        },
        {
            "text": "This aggregation can be reproduced in an analogous manner in vitro, using cell-based as well as cell-free assays. ",
            "section": "INTRODUCTION"
        },
        {
            "text": "The evolved PrP Sc like isoforms -termed PrP res -harbor similar biochemical characteristics like resistance to Proteinase K and detection by same antibodies.",
            "section": "INTRODUCTION"
        },
        {
            "text": "Accumulation of PrP Sc in the central nervous system (CNS) is accompanied by neurological dysfunctions, neuronal vacuolation, and astrocytic gliosis. ",
            "section": "INTRODUCTION"
        },
        {
            "text": "Although the exact disease causing mechanism is unknown to date, there is evidence for a general neurotoxicity of these aggregates, which deteriorate synaptic function and induce oxidative stress and membrane disruption (Soto and Estrada, 2008). ",
            "section": "INTRODUCTION",
            "ref_spans": [
                {
                    "start": 220,
                    "end": 244,
                    "type": "bibr",
                    "ref_id": "b37",
                    "text": "(Soto and Estrada, 2008)"
                }
            ]
        },
        {
            "text": "Prion diseases belong to the group of protein misfolding diseases like Alzheimer's (AD), Parkinson's (PD), and Huntington's disease (HD), which are generally characterized by an incorrect folding process of a host encoded protein with a conformation different from its native structure. ",
            "section": "INTRODUCTION"
        },
        {
            "text": "The misfolding is followed by a self-aggregation and polymerization of the protein according to a \"seeding-nucleation\" process (Jarrett and Lansbury, 1993).",
            "section": "INTRODUCTION",
            "ref_spans": [
                {
                    "start": 127,
                    "end": 155,
                    "type": "bibr",
                    "ref_id": "b18",
                    "text": "(Jarrett and Lansbury, 1993)"
                }
            ]
        },
        {
            "text": "As PrP Sc formation and aggregation is the central event in prion diseases, the inhibition of oligomer formation and fibril extension as well as the enhancement of fibril degradation are major targets for the development of therapeutic strategies against TSEs. ",
            "section": "INTRODUCTION"
        },
        {
            "text": "Several substances have been identified which inhibit PrP res formation and accumulation in vitro and prolonged survival in scrapie-infected animals: Congo red (Caughey and Race, 1992), branched polyamines (Supattapone et al., 2001), porphyrins and phthalocyanines (Priola et al., 2000;Caughey et al., 2007), heparan sulfate mimetics (Adjou et al., 2003), amphotericin (Mange et al., 2000), curcumine (Caughey et al., 2003;Yang et al., 2009), and tetracyclines (De Luigi et al., 2008). ",
            "section": "INTRODUCTION",
            "ref_spans": [
                {
                    "start": 160,
                    "end": 184,
                    "type": "bibr",
                    "ref_id": "b2",
                    "text": "(Caughey and Race, 1992)"
                },
                {
                    "start": 206,
                    "end": 232,
                    "type": "bibr",
                    "ref_id": "b38",
                    "text": "(Supattapone et al., 2001)"
                },
                {
                    "start": 265,
                    "end": 286,
                    "type": "bibr",
                    "ref_id": "b31",
                    "text": "(Priola et al., 2000;"
                },
                {
                    "start": 286,
                    "end": 307,
                    "type": "bibr",
                    "ref_id": "b4",
                    "text": "Caughey et al., 2007)"
                },
                {
                    "start": 334,
                    "end": 354,
                    "type": "bibr",
                    "ref_id": "b0",
                    "text": "(Adjou et al., 2003)"
                },
                {
                    "start": 369,
                    "end": 389,
                    "type": "bibr",
                    "ref_id": "b28",
                    "text": "(Mange et al., 2000)"
                },
                {
                    "start": 401,
                    "end": 423,
                    "type": "bibr",
                    "ref_id": "b3",
                    "text": "(Caughey et al., 2003;"
                },
                {
                    "start": 423,
                    "end": 441,
                    "type": "bibr",
                    "ref_id": "b44",
                    "text": "Yang et al., 2009)"
                },
                {
                    "start": 461,
                    "end": 484,
                    "type": "bibr",
                    "ref_id": "b5",
                    "text": "(De Luigi et al., 2008)"
                }
            ]
        },
        {
            "text": "However, for various reasons none of these compounds has been included in prevention and treatment regimes for humans yet. ",
            "section": "INTRODUCTION"
        },
        {
            "text": "Most recently two new substance classes, benzothiazoles (Geissen et al., 2011) and diphenylpyrazoles (Leidel et al., 2011), were identified by high-throughput screening approaches that inhibit PrP res accumulation in cell culture models and prolong incubation times in scrapie-infected mice.",
            "section": "INTRODUCTION",
            "ref_spans": [
                {
                    "start": 56,
                    "end": 78,
                    "type": "bibr",
                    "ref_id": "b11",
                    "text": "(Geissen et al., 2011)"
                },
                {
                    "start": 101,
                    "end": 122,
                    "type": "bibr",
                    "ref_id": "b24",
                    "text": "(Leidel et al., 2011)"
                }
            ]
        },
        {
            "text": "Other therapeutic strategies rely on passive immunization (White et al., 2003), RNA interference (Pfeifer et al., 2006), RNA aptamers (Proske et al., 2002), copper chelating antibiotics (Murakami-Kubo et al., 2004), or on the induction of autophagy by Lithium (Heiseke et al., 2009).",
            "section": "INTRODUCTION",
            "ref_spans": [
                {
                    "start": 58,
                    "end": 78,
                    "type": "bibr",
                    "ref_id": "b43",
                    "text": "(White et al., 2003)"
                },
                {
                    "start": 97,
                    "end": 119,
                    "type": "bibr",
                    "ref_id": "b30",
                    "text": "(Pfeifer et al., 2006)"
                },
                {
                    "start": 134,
                    "end": 155,
                    "type": "bibr",
                    "ref_id": "b32",
                    "text": "(Proske et al., 2002)"
                },
                {
                    "start": 186,
                    "end": 214,
                    "type": "bibr",
                    "ref_id": "b29",
                    "text": "(Murakami-Kubo et al., 2004)"
                },
                {
                    "start": 260,
                    "end": 282,
                    "type": "bibr",
                    "ref_id": "b16",
                    "text": "(Heiseke et al., 2009)"
                }
            ]
        },
        {
            "text": "Recent studies on AD suggest that phenolic compounds like green tea epigallocatechin gallate (Rezai-Zadeh et al., 2005), herb extracts like grape seed polyphenolic extract (Wang et al., 2009;Liu et al., 2011), or medicinal herbs like Paeonia suffruticosa (Fujiwara et al., 2009) can be used for the treatment of neurodegenerative diseases.",
            "section": "INTRODUCTION",
            "ref_spans": [
                {
                    "start": 93,
                    "end": 119,
                    "type": "bibr",
                    "ref_id": "b33",
                    "text": "(Rezai-Zadeh et al., 2005)"
                },
                {
                    "start": 172,
                    "end": 191,
                    "type": "bibr",
                    "ref_id": "b42",
                    "text": "(Wang et al., 2009;"
                },
                {
                    "start": 191,
                    "end": 208,
                    "type": "bibr",
                    "ref_id": "b26",
                    "text": "Liu et al., 2011)"
                },
                {
                    "start": 255,
                    "end": 278,
                    "type": "bibr",
                    "ref_id": "b10",
                    "text": "(Fujiwara et al., 2009)"
                }
            ]
        },
        {
            "text": "The here presented study shows that the American skullcap Scutellaria lateriflora, a traditional medical herb in North America, exhibits strong anti-prion activity. ",
            "section": "INTRODUCTION"
        },
        {
            "text": "Extracts of this plant have been traditionally used as sedative and for the treatment of insomnia, anxiety, or neuralgia (Foster, 1996). ",
            "section": "INTRODUCTION",
            "ref_spans": [
                {
                    "start": 121,
                    "end": 135,
                    "type": "bibr",
                    "ref_id": "b8",
                    "text": "(Foster, 1996)"
                }
            ]
        },
        {
            "text": "Moreover, we can show here that the crude aqueous extract inhibits prion propagation and dissolves prion aggregates in vitro. ",
            "section": "INTRODUCTION"
        },
        {
            "text": "Continuous oral administration of S. lateriflora tea (water extract) significantly prolonged incubation times in scrapie-infected mice. ",
            "section": "INTRODUCTION"
        },
        {
            "text": "Notably, the natural constituents, the flavonoids baicalein and baicalin-hydrate, exhibit the same inhibitory effects on prion propagation and dissolve existing fibrils.",
            "section": "INTRODUCTION"
        },
        {
            "text": "Baicalein and baicalein-hydrate were purchased from Sigma-Aldrich and solubilized in DMSO. ",
            "section": "FLAVONOIDS AND TEA OF SCUTELLARIA LATERIFLORA"
        },
        {
            "text": "The dried herb S. lateriflora was purchased from Goldener Zweig (Buchholz, Germany). ",
            "section": "FLAVONOIDS AND TEA OF SCUTELLARIA LATERIFLORA"
        },
        {
            "text": "Water extracts (tea) were prepared by mixing 30 g of sliced dry herbs in 1.0 l boiling water for 30 min. ",
            "section": "FLAVONOIDS AND TEA OF SCUTELLARIA LATERIFLORA"
        },
        {
            "text": "After cooling the tea was administered directly to mice. ",
            "section": "FLAVONOIDS AND TEA OF SCUTELLARIA LATERIFLORA"
        },
        {
            "text": "For in vitro experiments tea was lyophilized to yield dried extracts. ",
            "section": "FLAVONOIDS AND TEA OF SCUTELLARIA LATERIFLORA"
        },
        {
            "text": "In cell-based assays the dried material was resuspended in H 2 O, concentrated by a factor of 10 (termed tea concentrate) and added to the cell culture medium. ",
            "section": "FLAVONOIDS AND TEA OF SCUTELLARIA LATERIFLORA"
        },
        {
            "text": "In cell-free conversion assay the dried extract was directly resuspended in the conversion buffer in a final volume of 20 \u03bcl.",
            "section": "FLAVONOIDS AND TEA OF SCUTELLARIA LATERIFLORA"
        },
        {
            "text": "C57Bl/6 mice were inoculated with cloned mouse scrapie strains RML intracerebrally (i.c.; 30 \u03bcl of 1% mouse brain homogenate) or intraperitoneally (i.p.; 50 \u03bcl of 1% brain homogenate). ",
            "section": "PROPAGATION OF SCRAPIE STRAINS"
        },
        {
            "text": "The health status of the mice was inspected daily, and their body weights were recorded weekly. ",
            "section": "PROPAGATION OF SCRAPIE STRAINS"
        },
        {
            "text": "After the onset of TSE-associated clinical symptoms (and weight loss, abnormal tail tonus, hind limb paralysis), the animals were euthanized. ",
            "section": "PROPAGATION OF SCRAPIE STRAINS"
        },
        {
            "text": "The incubation times were calculated as the time between inoculation and death. ",
            "section": "PROPAGATION OF SCRAPIE STRAINS"
        },
        {
            "text": "The brains were removed and kept as following: one half of each brain was stored at \u221220\u02daC, and the other half was fixed in 4% neutral buffered formalin.",
            "section": "PROPAGATION OF SCRAPIE STRAINS"
        },
        {
            "text": "Pathogenic isoform for PrP conversion reactions was purified from brains of C57/Bl6 mice i.c. inoculated with mouse scrapie strain Me7. ",
            "section": "PROPAGATION OF SCRAPIE STRAINS"
        },
        {
            "text": "Brains were taken at the beginning of clinical symptoms in the animals and stored at \u221220\u02daC. ",
            "section": "PROPAGATION OF SCRAPIE STRAINS"
        },
        {
            "text": "PrP Sc was purified according to Eiden et al. (2006).",
            "section": "PROPAGATION OF SCRAPIE STRAINS",
            "ref_spans": [
                {
                    "start": 33,
                    "end": 52,
                    "type": "bibr",
                    "ref_id": "b7",
                    "text": "Eiden et al. (2006)"
                }
            ]
        },
        {
            "text": "Before embedding in paraffin the formalin fixed brain was cut at five different levels to reveal caudal medulla, rostral medulla, midbrain, thalamic, and frontal slices. ",
            "section": "HEMATOXYLIN AND EOSIN STAINING AND IMMUNOHISTOCHEMISTRY"
        },
        {
            "text": "Lesion profile scoring was carried out on Hematoxylin and Eosin (H&E) stained sections according to standard methodology (Fraser and Dickinson, 1968). ",
            "section": "HEMATOXYLIN AND EOSIN STAINING AND IMMUNOHISTOCHEMISTRY",
            "ref_spans": [
                {
                    "start": 121,
                    "end": 149,
                    "type": "bibr",
                    "ref_id": "b9",
                    "text": "(Fraser and Dickinson, 1968)"
                }
            ]
        },
        {
            "text": "For immunohistochemistry samples were processed (with minor modifications) as described previously (Hardt et al., 2000). ",
            "section": "HEMATOXYLIN AND EOSIN STAINING AND IMMUNOHISTOCHEMISTRY",
            "ref_spans": [
                {
                    "start": 99,
                    "end": 119,
                    "type": "bibr",
                    "ref_id": "b15",
                    "text": "(Hardt et al., 2000)"
                }
            ]
        },
        {
            "text": "Three micrometers section were de-paraffinized and rehydrated. ",
            "section": "HEMATOXYLIN AND EOSIN STAINING AND IMMUNOHISTOCHEMISTRY"
        },
        {
            "text": "Pretreatment included an incubation step with 98% formic acid (15 min) and blocking of the endogenous peroxidase activity with 3% H 2 O 2 /methanol (30 min) followed by autoclaving in citrate buffer (pH 6.0, 20 min). ",
            "section": "HEMATOXYLIN AND EOSIN STAINING AND IMMUNOHISTOCHEMISTRY"
        },
        {
            "text": "The monoclonal antibody SAF 84 was applied at a dilution of 1:2000 for 2 h at room temperature and detected by avidin-biotin-horseradish peroxidase (Vector Elite). ",
            "section": "HEMATOXYLIN AND EOSIN STAINING AND IMMUNOHISTOCHEMISTRY"
        },
        {
            "text": "Color reactions were finally developed using diaminobenzidine (DAB) substrate.",
            "section": "HEMATOXYLIN AND EOSIN STAINING AND IMMUNOHISTOCHEMISTRY"
        },
        {
            "text": "Mouse brain samples 10% (w/v) were prepared in lysis buffer (0.42 mM sucrose solution containing 0.5% deoxycholic acid sodium salt (DOC) and 0.5% Non-idet P40) and incubated with PK (50 \u03bcg/ml, final concentration) for 60 min at 55\u02daC. ",
            "section": "PROTEINASE K DIGESTION AND SODIUM PHOSPHOTUNGSTIC ACID PRECIPITATION"
        },
        {
            "text": "Reactions were stopped with pefabloc (Roche) followed by incubation with 0.3% (w/v) phosphotungstic acid precipitation (PTA) and selective precipitation of PrP Sc according to Gretzschel et al. (2005).",
            "section": "PROTEINASE K DIGESTION AND SODIUM PHOSPHOTUNGSTIC ACID PRECIPITATION",
            "ref_spans": [
                {
                    "start": 176,
                    "end": 200,
                    "type": "bibr",
                    "ref_id": "b12",
                    "text": "Gretzschel et al. (2005)"
                }
            ]
        },
        {
            "text": "Cell-free conversion studies were performed as described before (Eiden et al., 2006;Kupfer et al., 2007). ",
            "section": "PRP CONVERSION REACTION",
            "ref_spans": [
                {
                    "start": 64,
                    "end": 84,
                    "type": "bibr",
                    "ref_id": "b7",
                    "text": "(Eiden et al., 2006;"
                },
                {
                    "start": 84,
                    "end": 104,
                    "type": "bibr",
                    "ref_id": "b23",
                    "text": "Kupfer et al., 2007)"
                }
            ]
        },
        {
            "text": "For the conversion reaction 400 ng of recombinant ovine PrP C , expressed in E. coli, was incubated with 200-400 ng of purified PrP Sc in a conversion buffer [50 mM citrate buffer (pH 6.0), 200 mM KCl, 5 mM MgCl 2 , and 1.25% sarkosyl; Horiuchi et al., 2000]. ",
            "section": "PRP CONVERSION REACTION",
            "ref_spans": [
                {
                    "start": 236,
                    "end": 258,
                    "type": "bibr",
                    "ref_id": "b17",
                    "text": "Horiuchi et al., 2000]"
                }
            ]
        },
        {
            "text": "Standard conversion reactions were carried out for 3 days at 37\u02daC. ",
            "section": "PRP CONVERSION REACTION"
        },
        {
            "text": "Afterward, samples were incubated with PK (final concentration of 30 \u03bcg/ml) for 1 h at 37\u02daC. ",
            "section": "PRP CONVERSION REACTION"
        },
        {
            "text": "PK was diluted in TN-buffer (0.15 M NaCl, 0.05 M Tris/HCl pH 7.4). ",
            "section": "PRP CONVERSION REACTION"
        },
        {
            "text": "The reaction was stopped with PMSF (phenyl methansulfonyl fluoride; 10 mM). ",
            "section": "PRP CONVERSION REACTION"
        },
        {
            "text": "Twenty micrograms of a carrier protein (thyroglobulin) was added and the samples were incubated with a fourfold volume of methanol at -20\u02daC to precipitate the proteins. ",
            "section": "PRP CONVERSION REACTION"
        },
        {
            "text": "After centrifugation at 12000 g for 15 min, the proteins were pelleted and resolubilized by heating to 95\u02daC for 5 min in SDS-PAGE loading buffer [1% (w/v) SDS, 25 mM Tris/HCl pH 7.4, 0.5% mercaptoethanol, and 0.001% bromophenol blue].",
            "section": "PRP CONVERSION REACTION"
        },
        {
            "text": "Samples were separated on SDS-polyacrylamide gels containing 16% (w/v) acrylamide/bisacrylamide, 0.375 M Tris/HCl (pH 8.8), 0.5% (w/v) SDS (sodium dodecyl sulfate), 0.06% (w/v) APS (ammonium peroxydisulfate), and 0.06%",
            "section": "PRP CONVERSION REACTION"
        },
        {
            "text": "For immunoblotting proteins were transferred in a semidry chamber to a polyvinylidene difluoride (PVDF) membrane. ",
            "section": "PRP CONVERSION REACTION"
        },
        {
            "text": "Membranes were then incubated in blocking buffer (PBS-0.1% Tween 20, 5% non-fat dry milk powder) followed by incubation for 60 min with the monoclonal antibody (mab) P4 (RBiopharm), mab SAF-70 (SPIbio), or polyclonal antibody (pab) Ra 10 (Groschup et al., 1994, 1997). In contrast to mab P4, which detects ovine PrP C/res , pab Ra10 detects only murine PrP C/Sc . ",
            "section": "PRP CONVERSION REACTION",
            "ref_spans": [
                {
                    "start": 239,
                    "end": 261,
                    "type": "bibr",
                    "ref_id": "b14",
                    "text": "(Groschup et al., 1994"
                },
                {
                    "start": 261,
                    "end": 285,
                    "type": "bibr",
                    "ref_id": "b13",
                    "text": "(Groschup et al., , 1997"
                }
            ]
        },
        {
            "text": "Membranes were washed three times for 10 min with PBS containing 0.1% Tween 20 and then incubated with a secondary antibody bound to alkaline phosphatase (Goat-anti-mouse-alkaline phosphatase or goat anti-rabbit-peroxidase). ",
            "section": "PRP CONVERSION REACTION"
        },
        {
            "text": "After washing, the chemiluminescence substrate CDP-Star (Tropix) was applied and membranes were incubated for 5 min before the light signals were Frontiers in Psychiatry | Neurodegeneration recorded on a Versadoc Imaging System (Biorad). ",
            "section": "PRP CONVERSION REACTION"
        },
        {
            "text": "Visualization was carried out with the Biorad VersaDoc\u2122quantification software Quantity One. ",
            "section": "PRP CONVERSION REACTION"
        },
        {
            "text": "The percentage of converted substrate was calculated as: signal volume of PrP res digested with PK/signal volume of PrP C without PK * 10. ",
            "section": "PRP CONVERSION REACTION"
        },
        {
            "text": "Conversion rates were calculated for each time point as a mean value from four independent reactions. ",
            "section": "PRP CONVERSION REACTION"
        },
        {
            "text": "For stripping, membranes were incubated twice for 15 min with a buffer containing 0.2 M glycine (pH 2.0) and 1% SDS.",
            "section": "PRP CONVERSION REACTION"
        },
        {
            "text": "Two scrapie-infected mouse cell lines were used: ScN 2 Acells [RML infected neuroblastoma-(N 2 A)-cells] and SMB-cells (\"scrapie-mouse-brain,\" infected with strain 22F, a gift of TSE Resource Centre at the Institute for Animal Health, UK). ",
            "section": "PRP RES DETECTION FROM CELL CULTURE"
        },
        {
            "text": "ScN 2 Acells were cultured in Opti-MEM, 10% fetal calf serum (FCS), and 5% CO 2 at 37\u02daC. ",
            "section": "PRP RES DETECTION FROM CELL CULTURE"
        },
        {
            "text": "SMB-cells were cultured in MEM+ [MEM199, 10% newborn calf serum (NCS), 5% FCS] and 5% CO 2 at 35\u02daC.",
            "section": "PRP RES DETECTION FROM CELL CULTURE"
        },
        {
            "text": "The cell-based assay was carried out according to Leidel et al. (2011) with two scrapie-infected mouse cell lines: ScN 2 A-cells and SMB-cells. ",
            "section": "PRP RES DETECTION FROM CELL CULTURE",
            "ref_spans": [
                {
                    "start": 50,
                    "end": 70,
                    "type": "bibr",
                    "ref_id": "b24",
                    "text": "Leidel et al. (2011)"
                }
            ]
        },
        {
            "text": "These cells were adapted for dot blot procedure in 96-well plate format to identify potential inhibitors of PrP Sc formation. ",
            "section": "PRP RES DETECTION FROM CELL CULTURE"
        },
        {
            "text": "Compounds were resolved in DMSO and added to cells in eight replicates in concentrations of 10, 100, and 1000 \u03bcM (final concentration). ",
            "section": "PRP RES DETECTION FROM CELL CULTURE"
        },
        {
            "text": "After 3 days of incubation in a CO 2 -incubator, the supernatants were removed and cells lysed in 100 \u03bcl lysis buffer (50 mM Tris/HCl, 150 mM NaCl, 0.5% Na-deoxycholate, 0.5% TX-100, pH 8.0). ",
            "section": "PRP RES DETECTION FROM CELL CULTURE"
        },
        {
            "text": "Lysates were or electrophoresed and immunoblotted as described in the previous section or dot blotted on PVDF membranes using a 96-well dot blot apparatus (Transblotter, Roth). ",
            "section": "PRP RES DETECTION FROM CELL CULTURE"
        },
        {
            "text": "Dot blotting membranes were dried for 1 h at 37\u02daC and fixed sample incubated with DNAse (100 \u03bcg/ml) for 1 h at 37\u02daC. ",
            "section": "PRP RES DETECTION FROM CELL CULTURE"
        },
        {
            "text": "After rinsing the membranes twice with distilled water, the membrane was incubated with PK (25 \u03bcg/ml) for 90 min at 37\u02daC. ",
            "section": "PRP RES DETECTION FROM CELL CULTURE"
        },
        {
            "text": "The digestion was terminated using PMSF (2 mM) and membranes were rinsed in 3 M guanidium thiocyanate for 10 min followed by washing them five times in distilled water.",
            "section": "PRP RES DETECTION FROM CELL CULTURE"
        },
        {
            "text": "The incubation of the membrane with blocking buffer (PBS-0.1% Tween 20, 5% non-fat dry milk powder) was followed by an incubation for 60 min with polyclonal antibody (pab) Ra 10. ",
            "section": "PRP RES DETECTION FROM CELL CULTURE"
        },
        {
            "text": "Membranes were washed three times for 10 min with PBS containing 0.1% Tween 20 and then incubated with a secondary antibody bound to peroxidase (Goat anti-rabbit-PO). ",
            "section": "PRP RES DETECTION FROM CELL CULTURE"
        },
        {
            "text": "Afterward, the chemiluminescence substrate ECL (Roche) was applied and incubated on the membrane for 1 min before the light signals on the membrane were detected directly in a camera. ",
            "section": "PRP RES DETECTION FROM CELL CULTURE"
        },
        {
            "text": "The intensity of the PrP Sc signal of each well was quantified by using the Versadoc imaging system. ",
            "section": "PRP RES DETECTION FROM CELL CULTURE"
        },
        {
            "text": "The half maximal (50%) inhibitory concentration (IC 50 ) of each compound was calculated from eight independent reactions.",
            "section": "PRP RES DETECTION FROM CELL CULTURE"
        },
        {
            "text": "Survival times were analyzed by Kaplan-Meier Survival analysis using the log-rank test to compare the curves. ",
            "section": "STATISTICAL ANALYSIS"
        },
        {
            "text": "The Statistical analysis was done using SigmaBlot statistical software (San Jose, CA, USA). ",
            "section": "STATISTICAL ANALYSIS"
        },
        {
            "text": "Survival times are expressed as mean \u00b1 SD.",
            "section": "STATISTICAL ANALYSIS"
        },
        {
            "text": "The effect of S. lateriflora tea on the PrP res formation was first analyzed in vitro using two different scrapie-infected cell lines (SMB and ScN 2 A-cells), which permanently accumulate PrP res . ",
            "section": "RESULTS"
        },
        {
            "text": "When tea concentrate was added to the culture medium, a dose dependent reduction of PrP res accumulation was observed in SMB as well as ScN 2 A-cells (Figure 1). ",
            "section": "RESULTS",
            "ref_spans": [
                {
                    "start": 150,
                    "end": 160,
                    "type": "figure",
                    "ref_id": "fig_0",
                    "text": "(Figure 1)"
                }
            ]
        },
        {
            "text": "Cells were cultivated in T25 flasks and incubated with increasing amounts of S. lateriflora tea for 3 days. ",
            "section": "RESULTS"
        },
        {
            "text": "After this time, cells were harvested and the level of PK-resistant PrP res was assessed by Western blotting. ",
            "section": "RESULTS"
        },
        {
            "text": "A dilution of 1:500 induced a reduction of PrP res to 58% for ScN 2 A ( Figure 1A, lane 2) and to 64% for SMB ( Figure 1B, lane 2) cells compared to the control (Figures 1A,B, lane 1). ",
            "section": "RESULTS",
            "ref_spans": [
                {
                    "start": 72,
                    "end": 90,
                    "type": "figure",
                    "ref_id": "fig_0",
                    "text": "Figure 1A, lane 2)"
                },
                {
                    "start": 112,
                    "end": 130,
                    "type": "figure",
                    "ref_id": "fig_0",
                    "text": "Figure 1B, lane 2)"
                },
                {
                    "start": 161,
                    "end": 183,
                    "type": "figure",
                    "ref_id": "fig_0",
                    "text": "(Figures 1A,B, lane 1)"
                }
            ]
        },
        {
            "text": "Dilutions of 1:50 resulted in a reduction to 33% for ScN 2 A-cells ( Figure 1A, lane  3) and 57% for SMB-cells ( Figure 1B, lane 3). ",
            "section": "RESULTS",
            "ref_spans": [
                {
                    "start": 69,
                    "end": 88,
                    "type": "figure",
                    "ref_id": "fig_0",
                    "text": "Figure 1A, lane  3)"
                },
                {
                    "start": 113,
                    "end": 131,
                    "type": "figure",
                    "ref_id": "fig_0",
                    "text": "Figure 1B, lane 3)"
                }
            ]
        },
        {
            "text": "About 1:20 dilutions displayed reduction to 28% for ScN 2 A ( Figure 1A, lane 4) and 47% for SMB-cells ( Figure 1B, lane 4) and reached values of 28.7% for ScN 2 A-cells ( Figure 1A, lane 5) and 42.3% for SMBcells ( Figure 1B, lane 5). ",
            "section": "RESULTS",
            "ref_spans": [
                {
                    "start": 62,
                    "end": 80,
                    "type": "figure",
                    "ref_id": "fig_0",
                    "text": "Figure 1A, lane 4)"
                },
                {
                    "start": 105,
                    "end": 123,
                    "type": "figure",
                    "ref_id": "fig_0",
                    "text": "Figure 1B, lane 4)"
                },
                {
                    "start": 172,
                    "end": 190,
                    "type": "figure",
                    "ref_id": "fig_0",
                    "text": "Figure 1A, lane 5)"
                },
                {
                    "start": 216,
                    "end": 234,
                    "type": "figure",
                    "ref_id": "fig_0",
                    "text": "Figure 1B, lane 5)"
                }
            ]
        },
        {
            "text": "Relative inhibition by tea is depicted in Figure 1C.",
            "section": "RESULTS",
            "ref_spans": [
                {
                    "start": 42,
                    "end": 51,
                    "type": "figure",
                    "ref_id": "fig_0",
                    "text": "Figure 1C"
                }
            ]
        },
        {
            "text": "To test the direct effects of tea on the conversion of PrP C to PrP res , a cell-free conversion assay was used in which a purified murine PrP Sc template induced the conversion of recombinant cellular PrP C into a PK-resistant PrP res fragment (Eiden et al., 2006;Kupfer et al., 2007). ",
            "section": "RESULTS",
            "ref_spans": [
                {
                    "start": 245,
                    "end": 265,
                    "type": "bibr",
                    "ref_id": "b7",
                    "text": "(Eiden et al., 2006;"
                },
                {
                    "start": 265,
                    "end": 285,
                    "type": "bibr",
                    "ref_id": "b23",
                    "text": "Kupfer et al., 2007)"
                }
            ]
        },
        {
            "text": "Newly converted PrP res -fragments were detected by mab P4 (Figure 2A, lanes 1-2), while PrP Sc aggregates were visualized by the polyclonal antibody Ra10 (Figure 2B,  lanes 1-2). ",
            "section": "RESULTS",
            "ref_spans": [
                {
                    "start": 59,
                    "end": 81,
                    "type": "figure",
                    "ref_id": "fig_0",
                    "text": "(Figure 2A, lanes 1-2)"
                },
                {
                    "start": 155,
                    "end": 178,
                    "type": "figure",
                    "ref_id": "fig_0",
                    "text": "(Figure 2B,  lanes 1-2)"
                }
            ]
        },
        {
            "text": "Dried tea extract (3, 0.3, and 0.03 mg respectively) was added to the conversion assay, inhibited PrP res formation and led to clearance of PrP res -fragments (Figure 2A, lanes 3-6). ",
            "section": "RESULTS",
            "ref_spans": [
                {
                    "start": 159,
                    "end": 181,
                    "type": "figure",
                    "text": "(Figure 2A, lanes 3-6)"
                }
            ]
        },
        {
            "text": "Even 0.03 mg caused a reduced PrP res formation compared to the control (Figure 2A, lanes 7-8) by 23%.",
            "section": "RESULTS",
            "ref_spans": [
                {
                    "start": 72,
                    "end": 94,
                    "type": "figure",
                    "text": "(Figure 2A, lanes 7-8)"
                }
            ]
        },
        {
            "text": "Similar results were seen in the case of dissolution of PrP Sc aggregates after PK digestion ( Figure 2B). ",
            "section": "RESULTS",
            "ref_spans": [
                {
                    "start": 95,
                    "end": 105,
                    "type": "figure",
                    "text": "Figure 2B)"
                }
            ]
        },
        {
            "text": "In contrast to the control ( Figure 2B, lanes 1-2), PrP Sc aggregates were completely digested if co-incubated with 3.0 mg dried tea extract ( Figure 2B,  lanes 3-4), as well as with 0.3 mg ( Figure 2B, lanes 5-6). ",
            "section": "RESULTS",
            "ref_spans": [
                {
                    "start": 29,
                    "end": 50,
                    "type": "figure",
                    "ref_id": "fig_0",
                    "text": "Figure 2B, lanes 1-2)"
                },
                {
                    "start": 143,
                    "end": 165,
                    "type": "figure",
                    "ref_id": "fig_2",
                    "text": "Figure 2B,  lanes 3-4)"
                },
                {
                    "start": 192,
                    "end": 213,
                    "type": "figure",
                    "ref_id": "fig_3",
                    "text": "Figure 2B, lanes 5-6)"
                }
            ]
        },
        {
            "text": "About 0.03 mg dried tea extract induced a partial disaggregation of PrP Sc aggregates ( Figure 2B, lanes 7-8) by 40% compared to the control.",
            "section": "RESULTS",
            "ref_spans": [
                {
                    "start": 88,
                    "end": 109,
                    "type": "figure",
                    "text": "Figure 2B, lanes 7-8)"
                }
            ]
        },
        {
            "text": "To further characterize the underlying inhibitory mechanisms, two main polyphenolic compounds of this herbal extract, the flavonoids Baicalin (baicalein 7-O-glucuronide) and its aglycone baicalein (5,6,7-trihydroxyflavone), were studied with regard to their inhibitory properties. ",
            "section": "RESULTS"
        },
        {
            "text": "Both components have been isolated from this herb previously (Awad et al., 2003) und were also identified in this study as ingredients in the tea by LCMS-IT-TOF hybrid mass spectrometry (data not shown). ",
            "section": "RESULTS",
            "ref_spans": [
                {
                    "start": 61,
                    "end": 80,
                    "type": "bibr",
                    "ref_id": "b1",
                    "text": "(Awad et al., 2003)"
                }
            ]
        },
        {
            "text": "In addition, a structural analog to baicalein, the flavonoid epicatechin and quercetin were analyzed.",
            "section": "RESULTS"
        },
        {
            "text": "The potentially inhibitory effects on the PrP res accumulation and conversion were assayed by a cell-based dot blot assay system (Geissen et al., 2011) and the cell-free conversion assay. ",
            "section": "RESULTS",
            "ref_spans": [
                {
                    "start": 129,
                    "end": 151,
                    "type": "bibr",
                    "ref_id": "b11",
                    "text": "(Geissen et al., 2011)"
                }
            ]
        },
        {
            "text": "Structures, assay results, and half maximal (50%) inhibitory concentrations (IC 50 ) of both compounds are summarized in Table 1. ",
            "section": "RESULTS",
            "ref_spans": [
                {
                    "start": 121,
                    "end": 128,
                    "type": "table",
                    "ref_id": "tab_0",
                    "text": "Table 1"
                }
            ]
        },
        {
            "text": "The cell-based dot blot assay was carried out with two different scrapie-infected SMB and ScN 2 A-cells again. ",
            "section": "RESULTS"
        },
        {
            "text": "Cells were seeded in 96 wells and incubated with decreasing concentrations of the corresponding flavonoids (1 mM, 100 and 10 \u03bcM). ",
            "section": "RESULTS"
        },
        {
            "text": "IC 50 values of Baicalein ranged from 138 \u03bcM (SMB-cells) to 63.7 \u03bcM (ScN 2 Acells). ",
            "section": "RESULTS"
        },
        {
            "text": "Baicalin showed significantly lower inhibitory effects compared to baicalein in SMB-cells (IC 50 : >1000 \u03bcM) as well as in ScN 2 A-cells (IC 50 : 239.8 \u03bcM). ",
            "section": "RESULTS"
        },
        {
            "text": "Two additional flavonoids with similar structure, epicatechin, and quercetin, showed also strong inhibitory effects in both cell-types: epicatechin IC 50 values were 96.6 \u03bcM (ScN 2 A-cells) and 106.8 \u03bcM (SMB-cells) and quercetin IC 50 values were 36.8 \u03bcM (ScN 2 A-cells) and 274.3 \u03bcM (SMB-cells; Table 1). ",
            "section": "RESULTS",
            "ref_spans": [
                {
                    "start": 296,
                    "end": 303,
                    "type": "table",
                    "ref_id": "tab_0",
                    "text": "Table 1"
                }
            ]
        },
        {
            "text": "Baicalein displayed a strong dose dependent inhibitory effects to PrP res formation (IC 50 : 18.48 \u03bcM) and dissolution of PrP Sc aggregates (IC 50 : 41.56 \u03bcM) in the cell-free conversion assay, in contrast to baicalin which yielded IC 50 values of >1000 \u03bcM for PrP res inhibition and 440 \u03bcM for PrP Sc dissolution. ",
            "section": "RESULTS"
        },
        {
            "text": "Epicatechin and quercetin, although highly similar in structural to baicalein, showed no inhibitory effects in cell-free conversion with regards to PrP res formation and PrP Sc disintegration.",
            "section": "RESULTS"
        },
        {
            "text": "In summary, these data demonstrate that tea of S. lateriflora contains two active compounds, baicalein and baicalin, which are specific inhibitors of PrP C conversion and PrP res amplification in vitro as well as enhance the degradation of PrP Sc fibrils.",
            "section": "RESULTS"
        },
        {
            "text": "In another set of experiments in vivo effects of S. lateriflora tea were assessed. ",
            "section": "RESULTS"
        },
        {
            "text": "Wild-type mice were infected either by intracerebrally (i.c.) or intraperitoneally (i.p.) inoculation with mouse scrapie strain RML and the drinking water was replaced by freshly brewed tea starting 2 weeks prior to their inoculation and for the whole lifetime of the mice. ",
            "section": "RESULTS"
        },
        {
            "text": "Survival times are depicted in Figure 3. ",
            "section": "RESULTS",
            "ref_spans": [
                {
                    "start": 31,
                    "end": 39,
                    "type": "figure",
                    "text": "Figure 3"
                }
            ]
        },
        {
            "text": "Six Bl6/C57 mice were used for the treatment and compared to six intracerebrally inoculated mice which received normal drinking water. ",
            "section": "RESULTS"
        },
        {
            "text": "The mean life spans of the control group (Figure 5A, bold line) was 147 \u00b1 3.1 dpi (Figure 3B) whereas the tea treated mice (Figure 5A dashed line) survived significantly longer (184 \u00b1 26.7 dpi; Figure 3B). ",
            "section": "RESULTS",
            "ref_spans": [
                {
                    "start": 41,
                    "end": 63,
                    "type": "figure",
                    "ref_id": "fig_3",
                    "text": "(Figure 5A, bold line)"
                },
                {
                    "start": 82,
                    "end": 93,
                    "type": "figure",
                    "text": "(Figure 3B)"
                },
                {
                    "start": 123,
                    "end": 146,
                    "type": "figure",
                    "ref_id": "fig_3",
                    "text": "(Figure 5A dashed line)"
                },
                {
                    "start": 194,
                    "end": 204,
                    "type": "figure",
                    "text": "Figure 3B)"
                }
            ]
        },
        {
            "text": "Three of the treated mice survived up to 60 days compared to the control mice. ",
            "section": "RESULTS"
        },
        {
            "text": "In the case of i.p. inoculation of RML strain, a mean prolongation of 15 days was achieved (Figures 3C,D). ",
            "section": "RESULTS",
            "ref_spans": [
                {
                    "start": 91,
                    "end": 105,
                    "type": "figure",
                    "text": "(Figures 3C,D)"
                }
            ]
        },
        {
            "text": "The mean incubation time of the control group (Figure 3C, bold line) was 191 \u00b1 8.6 dpi ( Figure 3D) whereas the tea treated mice (Figure 3C, dashed line) survived significantly longer (206 \u00b1 8.6 dpi; Figure 3D).",
            "section": "RESULTS",
            "ref_spans": [
                {
                    "start": 46,
                    "end": 68,
                    "type": "figure",
                    "text": "(Figure 3C, bold line)"
                },
                {
                    "start": 89,
                    "end": 99,
                    "type": "figure",
                    "text": "Figure 3D)"
                },
                {
                    "start": 129,
                    "end": 153,
                    "type": "figure",
                    "text": "(Figure 3C, dashed line)"
                },
                {
                    "start": 200,
                    "end": 210,
                    "type": "figure",
                    "text": "Figure 3D)"
                }
            ]
        },
        {
            "text": "Brains of the i.c. infected mice were subjected to comparative biochemical and immunohistochemical investigations. ",
            "section": "RESULTS"
        },
        {
            "text": "PrP immunoblot analysis revealed no differences of PrP Sc banding patterns and total amounts of PrP Sc in both groups. ",
            "section": "RESULTS"
        },
        {
            "text": "The PrP Sc content in all brains was analyzed after PK digestion and selective precipitation of PrP Sc from corresponding mouse brain homogenates with sodium phosphotungstic acid (Figure 4). ",
            "section": "RESULTS",
            "ref_spans": [
                {
                    "start": 179,
                    "end": 189,
                    "type": "figure",
                    "ref_id": "fig_2",
                    "text": "(Figure 4)"
                }
            ]
        },
        {
            "text": "No differences",
            "section": "RESULTS"
        },
        {
            "text": "Tea of S. lateriflora inhibits formation of PrP res . ",
            "section": "FIGURE 2 | Western blot analysis of inhibition of PrP res formation and disaggregation of pre-existing PrP Sc fibrils in a cell-free conversion assay. (A)"
        },
        {
            "text": "Lanes 1-2 show PK-resistant PrP res -fragments in samples without tea, lanes 3-4 samples after co-incubation with 3.0 mg dried tea extract, lanes 5-6 with 0.3 mg dried tea extract, and lanes 7-8 co-incubation with 0.03 mg dried tea extract. ",
            "section": "FIGURE 2 | Western blot analysis of inhibition of PrP res formation and disaggregation of pre-existing PrP Sc fibrils in a cell-free conversion assay. (A)"
        },
        {
            "text": "Detection was carried out with mab P4. ",
            "section": "FIGURE 2 | Western blot analysis of inhibition of PrP res formation and disaggregation of pre-existing PrP Sc fibrils in a cell-free conversion assay. (A)"
        },
        {
            "text": "(B) Tea of S. lateriflora disaggregates pre-existing fibrils after digestion with PK. ",
            "section": "FIGURE 2 | Western blot analysis of inhibition of PrP res formation and disaggregation of pre-existing PrP Sc fibrils in a cell-free conversion assay. (A)"
        },
        {
            "text": "The membrane from (A) was stripped and incubated another time with pab Ra10. ",
            "section": "FIGURE 2 | Western blot analysis of inhibition of PrP res formation and disaggregation of pre-existing PrP Sc fibrils in a cell-free conversion assay. (A)"
        },
        {
            "text": "Lanes 1-2 show PK-resistant PrP res -fragments in samples without tea, lanes 3-4 samples after co-incubation with 3.0 mg dried tea extract, lanes 5-6 with 0.3 mg dried tea extract, and lanes 7-8 co-incubation with 0.03 mg dried tea extract. ",
            "section": "FIGURE 2 | Western blot analysis of inhibition of PrP res formation and disaggregation of pre-existing PrP Sc fibrils in a cell-free conversion assay. (A)"
        },
        {
            "text": "Western blot was analyzed by standard chemiluminescence method. ",
            "section": "FIGURE 2 | Western blot analysis of inhibition of PrP res formation and disaggregation of pre-existing PrP Sc fibrils in a cell-free conversion assay. (A)"
        },
        {
            "text": "+: incubation with proteinase K (PK).",
            "section": "FIGURE 2 | Western blot analysis of inhibition of PrP res formation and disaggregation of pre-existing PrP Sc fibrils in a cell-free conversion assay. (A)"
        },
        {
            "text": "in PrP Sc banding patterns or PK resistances was detected in mice which eventually developed scrapie in the tea treated and control group (Figure 4, lanes 2-13). ",
            "section": "FIGURE 2 | Western blot analysis of inhibition of PrP res formation and disaggregation of pre-existing PrP Sc fibrils in a cell-free conversion assay. (A)",
            "ref_spans": [
                {
                    "start": 138,
                    "end": 160,
                    "type": "figure",
                    "ref_id": "fig_0",
                    "text": "(Figure 4, lanes 2-13)"
                }
            ]
        },
        {
            "text": "The brain lesion profiles and PrP Sc deposition patterns in the different mouse brain regions were similar for the treated and the untreated mice (Figures 5A-D).",
            "section": "FIGURE 2 | Western blot analysis of inhibition of PrP res formation and disaggregation of pre-existing PrP Sc fibrils in a cell-free conversion assay. (A)",
            "ref_spans": [
                {
                    "start": 146,
                    "end": 160,
                    "type": "figure",
                    "ref_id": "fig_3",
                    "text": "(Figures 5A-D)"
                }
            ]
        },
        {
            "text": "The here presented study demonstrates that solubilized ingredients of S. lateriflora not only inhibit the scrapie fibril formation but also destabilize pre-formed PrP Sc fibrils in a concentration dependent manner. ",
            "section": "DISCUSSION"
        },
        {
            "text": "Main constituents of the herb were the polyphenolic flavonoids baicalin and baicalein, which were found at high concentrations in corresponding extracts. ",
            "section": "DISCUSSION"
        },
        {
            "text": "Both components in purified form showed dose dependent inhibitory properties and thus were the active constituents responsible for the herbs effects on scrapie fibril regulation.",
            "section": "DISCUSSION"
        },
        {
            "text": "The strongest effects displayed baicalein, the main metabolite of baicalin, which inhibited PrP res accumulation in both cell-based and cell-free assays and promoted the destabilization of PrP Sc fibrils at low concentrations. ",
            "section": "DISCUSSION"
        },
        {
            "text": "A possible molecular mechanism is based on direct binding to the PrP C and the formation of a stable PrP-baicalein/baicalin complex, which blocks PrP conversion and/or accumulation. ",
            "section": "DISCUSSION"
        },
        {
            "text": "In the same way the destabilization of pre-existing fibrils would be caused by a specific intercalation of baicalein/baicalin into \u03b2-sheet structures of the PrP Sc aggregates which may lead to a forced PrP Sc degradation by lysosomal proteases. ",
            "section": "DISCUSSION"
        },
        {
            "text": "Similar effects by Baicalein have been described for the inhibition of \u03b1-synuclein (Zhu et al., 2004) and amyloid-\u03b2 peptide (A\u03b2) fibrillization (Lu et al., 2011).   ",
            "section": "DISCUSSION",
            "ref_spans": [
                {
                    "start": 83,
                    "end": 101,
                    "type": "bibr",
                    "ref_id": "b45",
                    "text": "(Zhu et al., 2004)"
                },
                {
                    "start": 144,
                    "end": 161,
                    "type": "bibr",
                    "ref_id": "b27",
                    "text": "(Lu et al., 2011)"
                }
            ]
        },
        {
            "text": "PrP Sc from RML infected mouse brains and lanes 8-13 PrP Sc from RML infected mouse brains that were treated with tea from S. lateriflora. ",
            "section": "DISCUSSION"
        },
        {
            "text": "Western blot was carried out with pab Ra10 and analyzed by chemiluminescence method.",
            "section": "DISCUSSION"
        },
        {
            "text": "In our present study oral administration of S. lateriflora tea significantly prolonged incubation of mice either infected intracerebral or intraperitoneal. ",
            "section": "DISCUSSION"
        },
        {
            "text": "These effects can be explained by direct interference of baicalein to evolving PrP aggregates in the CNS. ",
            "section": "DISCUSSION"
        },
        {
            "text": "Baicalein is able to cross the blood brain barrier and ultimately reach the CNS (Tsai et al., 2002). ",
            "section": "DISCUSSION",
            "ref_spans": [
                {
                    "start": 80,
                    "end": 99,
                    "type": "bibr",
                    "ref_id": "b40",
                    "text": "(Tsai et al., 2002)"
                }
            ]
        },
        {
            "text": "Baicalin, on the other hand, may act as pro-drug: After oral uptake, the sugar residue is cleaved by enzymes in the intestinal tract to generate baicalein. ",
            "section": "DISCUSSION"
        },
        {
            "text": "The more lipophilic baicalein is better absorbed in the gastrointestinal tract and can then enter the brain via the blood system (Tarrag\u00f3 et al., 2008).",
            "section": "DISCUSSION",
            "ref_spans": [
                {
                    "start": 129,
                    "end": 151,
                    "type": "bibr",
                    "ref_id": "b39",
                    "text": "(Tarrag\u00f3 et al., 2008)"
                }
            ]
        },
        {
            "text": "Within the CNS, the inhibition and dissolution of prion aggregates by Baicalein could protect neuronal cells from membrane disruption and subsequent neuronal cell death. ",
            "section": "DISCUSSION"
        },
        {
            "text": "Additional antioxidant properties of baicalein on reactive oxygen species (ROS), which evolve during protein aggregation, may reinforce this neuroprotective effect (Li et al., 2010). ",
            "section": "DISCUSSION",
            "ref_spans": [
                {
                    "start": 164,
                    "end": 181,
                    "type": "bibr",
                    "ref_id": "b25",
                    "text": "(Li et al., 2010)"
                }
            ]
        },
        {
            "text": "Baicalein is able to minimize ROS by directly quenching free radicals or indirectly inducing antioxidant enzymes like superoxide dismutase and catalase (Shieh et al., 2000;Kang et al., 2011).",
            "section": "DISCUSSION",
            "ref_spans": [
                {
                    "start": 152,
                    "end": 172,
                    "type": "bibr",
                    "ref_id": "b36",
                    "text": "(Shieh et al., 2000;"
                },
                {
                    "start": 172,
                    "end": 190,
                    "type": "bibr",
                    "ref_id": "b19",
                    "text": "Kang et al., 2011)"
                }
            ]
        },
        {
            "text": "Direct effects on the prion conversion were also seen in other plant derived polyphenols like curcumin which is a strong inhibitor of prion conversion replication in vitro (Caughey et al., 2003). ",
            "section": "DISCUSSION",
            "ref_spans": [
                {
                    "start": 172,
                    "end": 194,
                    "type": "bibr",
                    "ref_id": "b3",
                    "text": "(Caughey et al., 2003)"
                }
            ]
        },
        {
            "text": "It is in vivo efficacy, however, remains controversial: the oral administration of curcumin had no significant effect on the onset of scrapie in hamsters (Caughey et al., 2003), whereas scrapie-infected mice significantly survived longer after oral treatment (Riemer et al., 2008). ",
            "section": "DISCUSSION",
            "ref_spans": [
                {
                    "start": 154,
                    "end": 176,
                    "type": "bibr",
                    "ref_id": "b3",
                    "text": "(Caughey et al., 2003)"
                },
                {
                    "start": 259,
                    "end": 280,
                    "type": "bibr",
                    "ref_id": "b35",
                    "text": "(Riemer et al., 2008)"
                }
            ]
        },
        {
            "text": "Effects of other polyphenols (e.g., tannic acid, katacine, and 2 -2 -bis epigallocatechin gallate) that interfere with PrP conversion in vitro were also studied in vivo (Kocisko et al., 2003). ",
            "section": "DISCUSSION",
            "ref_spans": [
                {
                    "start": 169,
                    "end": 191,
                    "type": "bibr",
                    "ref_id": "b21",
                    "text": "(Kocisko et al., 2003)"
                }
            ]
        },
        {
            "text": "However, neither these substances nor mixtures of natural compounds including polyphenolic tea extract and pine bark extracts displayed any effects on incubation periods in scrapie-infected animals (Kocisko et al., 2004).",
            "section": "DISCUSSION",
            "ref_spans": [
                {
                    "start": 198,
                    "end": 220,
                    "type": "bibr",
                    "ref_id": "b22",
                    "text": "(Kocisko et al., 2004)"
                }
            ]
        },
        {
            "text": "Up to now only few compounds have been reported that delay onset on prion diseases after oral treatment. ",
            "section": "DISCUSSION"
        },
        {
            "text": "This includes pravastatin (Vetrugno et al., 2009), which is involved in cholesterol biosynthesis and influences membrane structure and function, fucoidan (Doh-Ura et al., 2007), as well as amyloid dye derivatives (Kawasaki et al., 2007). ",
            "section": "DISCUSSION",
            "ref_spans": [
                {
                    "start": 26,
                    "end": 49,
                    "type": "bibr",
                    "ref_id": "b41",
                    "text": "(Vetrugno et al., 2009)"
                },
                {
                    "start": 154,
                    "end": 176,
                    "type": "bibr",
                    "ref_id": "b6",
                    "text": "(Doh-Ura et al., 2007)"
                },
                {
                    "start": 213,
                    "end": 236,
                    "type": "bibr",
                    "ref_id": "b20",
                    "text": "(Kawasaki et al., 2007)"
                }
            ]
        },
        {
            "text": "However, possible drug associated sideeffects have to be further evaluated. ",
            "section": "DISCUSSION"
        },
        {
            "text": "Recently, diphenyl-pyrazoles (Leidel et al., 2011) were identified as a new class of anti-prion compounds, which prolong incubation time of scrapie-infected mice even after oral application.",
            "section": "DISCUSSION",
            "ref_spans": [
                {
                    "start": 29,
                    "end": 50,
                    "type": "bibr",
                    "ref_id": "b24",
                    "text": "(Leidel et al., 2011)"
                }
            ]
        },
        {
            "text": "In conclusion, beneficial effects of S. lateriflora tea can be explained by the anti-aggregatory and potential anti-oxidative effects of its natural constituents, baicalein and baicalin. ",
            "section": "DISCUSSION"
        },
        {
            "text": "Only few studies were conducted with herbal extracts of S. lateriflora for prevention and therapy of protein misfolding diseases to date. ",
            "section": "DISCUSSION"
        },
        {
            "text": "Results shown here for prion diseases are promising also in the context of other diseases in this group.",
            "section": "DISCUSSION"
        },
        {
            "text": "The LCMS-IT-TOF analysis was carried out by Andreas Link and Andrea Bodtke, Institute of Pharmacy, Ernst-Moritz-Arndt-University Greifswald, Greifswald, Germany.",
            "section": "ACKNOWLEDGMENTS"
        },
        {
            "text": "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.",
            "section": "Conflict of Interest Statement:"
        }
    ]
}